We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Noble Life Sciences Announces Appointment of Alain Cappeluti as President

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

"I am delighted to lead Noble Life Sciences' experienced and talented team as we launch new services to expand our current offering," said Mr. Cappeluti. "A focus of our development efforts has been to establish a biomarker based platform that leverages validated cancer pathway biomarkers measured in cell lines and tumor tissues to predict and evaluate sensitivity to targeted therapeutics across cancer indications and molecular sub-types. This effort has been supported by a Translational Research Award we received in 2010 from The Department of Business and Economic Development, Maryland Biotechnology Center."

Mr. Cappeluti has more than 25 years of experience in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. Mr. Cappeluti was the second employee at HGS and was part of the team that spun out CoGenesys from HGS in 2006 until the company was sold to Teva Pharmaceuticals in 2008. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He is also a co-founder and serves on the board of OTraces, Inc., an early stage cancer diagnostics company and is on the board of and serves as a consultant to other life science companies.

Dr. Carter remarked, "I am very pleased to assume the duties of Chairman of the Board of Noble Life Sciences as I move on to a new position as President and CEO of NexImmune. Mr. Cappeluti will take the lead at Noble Life Sciences during a very exciting time as the company expands its presence in the Maryland biotechnology market."